LUMEN-1 Trial Protocol Published in The Journal of Nuclear Medicine – EORTC
European Organisation for Research and Treatment of Cancer (EORTC) shared a post on LinkedIn:
“New publication alert!
We’re proud to announce the publication of the LUMEN-1 trial protocol in the The Journal of Nuclear Medicine – JNM by Nathalie Albert et al.!
The LUMEN-1 (EORTC-2334-BTG) randomised phase II trial investigates [¹⁷⁷Lu]Lu-DOTATATE for patients with recurrent meningioma, a population with limited treatment options after surgery and radiotherapy.
This is the first prospective, randomised clinical trial to evaluate the efficacy of SSTR2-targeted radionuclide therapy in this setting. The trial also includes a robust translational research programme leveraging: PET imaging and radiomics, tumour tissue profiling (genetic, epigenetic, IHC) and dosimetry and machine learning.
This work may pave the way for novel treatment strategies in neuro-oncology.”
More posts featuring European Organisation for Research and Treatment of Cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023